business

City Therapeutics Secures $200 Million in Increased US IPO

16 Ekim 2026Bloomberg

City Therapeutics Inc. raised $200 million in its US IPO, indicating strong investor interest in RNAi-based therapies.
City Therapeutics Inc. successfully raised $200 million through its initial public offering (IPO) in the United States.
The IPO was priced at the mid-point of its marketed range, reflecting strong investor interest in the company’s RNAi-based drug development. This funding will likely bolster its research and development efforts as it advances its innovative therapies.
City Therapeutics is among a wave of biotech companies tapping into public markets to fund their innovative drug development. The demand for novel therapies, particularly those utilizing RNAi technology, has surged as the healthcare landscape increasingly prioritizes precision medicine.
The successful IPO indicates a growing confidence in biotech firms focusing on RNA interference technology, a field that has seen significant advancements and potential for transformative therapies. City Therapeutics' ability to attract substantial investment at this stage suggests that investors are optimistic abou…

NewsAI özeti

This article is for informational purposes only and does not constitute financial advice.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.